Intermediate and high risk, resected gastro-intestinal stromal tumours expressing kit: RCT of adjuvant imatinib mesylate

Project Description

Gastro-intestinal stromal tumours (GIST) are rare cancers affecting about 100 Australians annually, Until recently surgery to remove GIST was the only effective treatment.

In 50% of people having an operation the disease returns within 5 years. Imatinib mesylate (IM) is a drug targeting a part of the biochemical pathway that influences tumour growth.

The drug prolongs life in people whose GIST is no longer operable. This study compares the impact of imatinib mesylate given after surgery to surgery alone on length of life in people at high risk of the GIST returning.

Scientific description

Intermediate and high risk, resected gastro-intestinal stromal tumours expressing kit:  RCT of adjuvant imatinib mesylate.

Year

2005-07

Researchers

Professor J Simes (2005, 2007), Professor John Zalcberg (2005, 2007), P Waring (2005), A/Prof B Mann (2005, 2007), A/ Prof M Smithers (2005, 2007), D Kotasek (2005, 2007), Dr Guy Van Hazel (WA) (2007)

Collaborators

G Van Hazel (2005)

Institution

Peter MacCallum Cancer Centre

Award / Duration

Multi-State Research Grant: 2005-2007

Funding

$13,334

Updated: 01 Jul, 2005